Biomarkers of ovarian reserve

Biomarkers in Medicine

Volumn 7, Issue 1, 2013, Pages 147-158

  Iliodromiti, Stamatina ^a   Nelson, Scott M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

AFC; age; AMH; anti m llerian hormone; antral follicle count; in vitro fertilization; IVF; OHSS; ovarian hyperstimulation syndrome; poor ovarian response; primordial follicle

Indexed keywords

BIOLOGICAL MARKER; FOLLITROPIN; FOLLITROPIN RECEPTOR; FRAGILE X MENTAL RETARDATION PROTEIN; GONADOTROPIN; INHIBIN B; LETROZOLE; MUELLERIAN INHIBITING FACTOR;

AGE; ANTRAL FOLLICLE COUNT; CLOMIPHENE CITRATE CHALLENGE TEST; ENDOCRINE FUNCTION TEST; EXOGENOUS FSH OVARIAN RESERVE TEST; FEMALE GENITAL TRACT PARAMETERS; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FMR1 GENE; GENE MUTATION; GONADOTROPIN RELEASING HORMONE AGONIST STIMULATION TEST; HORMONE ACTION; HUMAN; OVARIAN RESERVE; OVARY BLOOD FLOW; OVARY CYCLE; OVARY FOLLICLE; PREGNANCY; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ULTRASOUND;

ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; FOLLICLE STIMULATING HORMONE; FRAGILE X MENTAL RETARDATION PROTEIN; HUMANS; INHIBINS; OVARIAN FOLLICLE; POLYMORPHISM, GENETIC; RECEPTORS, FSH;

EID: 84873419764     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.97     Document Type: Review

References (72)

1. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 428(6979), 145-150 (2004).
2. Johnson J, Bagley J, Skaznik-Wikiel M et al. Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. Cell 122(2), 303-315 (2005).
3. Telfer EE, Gosden RG, Byskov AG et al. On regenerating the ovary and generating controversy. Cell 122(6), 821-822 (2005).
4. White YAR, Woods DC, Takai Y, Ishihara O, Deki H, Tilly JL. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. Nat. Med. 18(3), 413-421 (2012).
5. Telfer EE, Albertini DF. The quest for human ovarian stem cells. Nat. Med. 18(3), 353-354 (2012).
6. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One 5(1), e8772 (2010).
7. Tabor A. Genetic amniocentesis. Indications and risks. Dan. Med. Bull. 35(6), 520-537 (1988).
8. Hunt PA, Hassold TJ. Human female meiosis: what makes a good egg go bad? Trends Gen. 24, 86-93 (2008).
9. Hultén MA, Patel S, Jonasson J, Iwarsson E. On the origin of the maternal effect in trisomy 21 down syndrome; the oocyte mosaicism selection model. Reproduction 13, 1-9 (2010).
10. Haadsma ML, Mooij TM, Groen H et al. A reduced size of the ovarian follicle pool is associated with an increased risk of a trisomic pregnancy in IVF-treated women. Hum. Reprod. 25(2), 552-558 (2010).
11. Handyside AH, Montag M, Magli MC et al. Multiple meiotic errors caused by predivision of chromatids in women of advanced maternal age undergoing in vitro fertilisation. Eur. J. Hum. Genet. 20(7), 742-747 (2012).
12. Al-Inany HG, Youssef MA, Aboulghar M et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst. Rev. 5, CD001750 (2011).
13. Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum. Reprod. 26(10), 2593-2597 (2011).
14. Klinkert ER, Broekmans FJ, Looman CW, Te Velde ER. A poor response in the first in vitro fertilization cycle is not necessarily related to a poor prognosis in subsequent cycles. Fertil. Steril. 81(5), 1247-1253 (2004).
15. Hendriks DJ, Te Velde ER, Looman CW, Bancsi LF, Broekmans FJ. Expected poor ovarian response in predicting cumulative pregnancy rates: a powerful tool. Reprod. Biomed. Online 17(5), 727-736 (2008).
16. Broekmans FJ, de Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil. Steril. 94(3), 1044-1051 (2010).
17. Deb S, Jayaprakasan K, Campbell BK, Clewes JS, Johnson IR, Raine-Fenning NJ. Intraobserver and interobserver reliability of automated antral follicle counts made using three-dimensional ultrasound and SonoAVC. Ultrasound Obstet. Gynecol. 33(4), 477-483 (2009).
18. Jayaprakasan K, Jayaprakasan R, Al-Hasie HA et al. Can quantitative three-dimensional power Doppler angiography be used to predict ovarian hyperstimulation syndrome? Ultrasound Obstet. Gynecol. 33(5), 583-591 (2009).
19. Jayaprakasan K, Deb S, Batcha M et al. The cohort of antral follicles measuring 2-6 mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Müllerian hormone and response to controlled ovarian stimulation. Fertil. Steril. 94(5), 1775-1781 (2010).
20. Jayaprakasan K, Hilwah N, Kendall NR et al. Does 3D ultrasound offer any advantage in the pretreatment assessment of ovarian reserve and prediction of outcome after assisted reproduction treatment? Hum. Reprod. 22(7), 1932-1941 (2007).
21. National Collaborating Centre for Women's and Children's Health. Fertility: Assessment and Treatment for People with fertility Problems (Update). Royal College of Obstetricians and Gynaecologists Press, UK (2012).
22. Hsu A, Arny M, Knee AB et al. Antral follicle count in clinical practice: analyzing clinical relevance. Fertil. Steril. 95(2), 474-479 (2011).
23. Frattarelli JL, Lauria-Costab DF, Miller BT, Bergh PA, Scott RT. Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles. Fertil. Steril. 74(3), 512-517 (2000).
24. Broer SL, Dólleman M, Opmeer BC et al. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum. Reprod. Update 17(1), 46-54 (2011).
25. Hendriks DJ, Kwee J, Mol BW, Te Velde ER, Broekmans FJ. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil. Steril. 87(4), 764-775 (2007).
26. Melo MA, Garrido N, Alvarez C et al. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil. Steril. 91(1), 148-156 (2009).
27. Holte J, Brodin T, Berglund L, Hadziosmanovic N, Olovsson M, Bergh T. Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic ovaries. Fertil. Steril. 96(3), 594-599 (2011).
28. Jayaprakasan K, Al-Hasie H, Jayaprakasan R et al. The three-dimensional ultrasonographic ovarian vascularity of women developing poor ovarian response during assisted reproduction treatment and its predictive value. Fertil. Steril. 92(6), 1862-1869 (2009).
29. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy Ch, Englert Y. Stable serum levels of anti-Müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum. Reprod. 22(7), 1837-1840 (2007).
30. Van der Steeg JW, Steures P, Eijkemans MJ et al. Predictive value and clinical impact of basal follicle-stimulating hormone in subfertile, ovulatory women. J. Clin. Endocrinol. Metab. 92(6), 2163-2168 (2007).
31. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. Update 12(6), 685-718 (2006).
32. Rosen MP, Johnstone E, McCulloch CE et al. A characterization of the relationship of ovarian reserve markers with age. Fertil. Steril. 97(1), 238-243 (2012).
33. Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum. Reprod. Update 13(6), 559-565 (2007).
34. Riggs RM, Duran EH, Baker MW et al. Assessment of ovarian reserve with anti-Müllerian hormone: a comparison of the predictive value of anti-Müllerian hormone, follicle-stimulating hormone, inhibin B, and age. Am. J. Obstet. Gynecol. 199(2), 202.e1-202.e8 (2008).
35. Tan R, Pu D, Liu L, Liu J, Wu J. Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization. Fertil. Steril. 96(4), 905-911 (2011).
36. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS; ESHRE special interest group for reproductive endocrinology AMH round table. Anti-mullerian hormone (AMH): what do we still need to know? Hum. Reprod. 24(9), 2264-2275 (2009).
37. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil. Steril. 95(1), 170-175 (2011).
38. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod. Biomed. Online 23(4), 411-420 (2011).
39. Van Disseldorp J, Lambalk CB, Kwee J et al. Comparison of inter-and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum. Reprod. 25(1), 221-227 (2010).
40. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One 6(7), e22024 (2011).
41. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. Fertil. Steril. 95(2), 736-741 (2011).
42. Nelson SM, Messow MC, McConnachie A et al. External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients. Reprod. Biomed. Online 23(2), 204-206 (2011).
43. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum. Reprod. Update 16(2), 113-130 (2010).
44. Nelson SM, Yates RW, Fleming R. Serum Anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles: implications for individualization of therapy. Hum. Reprod. 22(9), 2414-2421 (2007).
45. Nelson SM, Yates RW, Lyall H et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum. Reprod. 24(4), 867-875 (2009).
46. Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil. Steril. 91(3), 705-714 (2009).
47. Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum. Reprod. 23(3), 699-708 (2008).
48. Sowers MR, Eyvazzadeh AD, McConnell D et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J. Clin. Endocrinol. Metab. 93(9), 3478-3483 (2008).
49. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J. Clin. Endocrinol. Metab. 96(5), 1336-1343 (2011).
50. Rousseau-Merck MF, Atger M, Loosfelt H, Milgrom E, Berger R. The chromosomal localization of the human follicle-stimulating hormone receptor gene (FSHR) on 2p21-p16 is similar to that of the luteinizing hormone receptor gene. Genomics 15(1), 222-224 (1993).
51. Nordhoff V, Sonntag B, von Tils D et al. Effects of the FSH receptor gene polymorphism p.N680S on cAMP and steroid production in cultured primary human granulosa cells. Reprod. Biomed. Online 23(2), 196-203 (2011).
52. Yao Y, Ma CH, Tang HL, Hu YF. Influence of follicle-stimulating hormone receptor (FSHR) Ser680Asn polymorphism on ovarian function and in-vitro fertilization outcome: a meta-analysis. Mol. Genet. Metab. 103(4), 388-393 (2011).
53. Mohiyiddeen L, Newman WG, McBurney H, Mulugeta B, Roberts SA, Nardo LG. Follicle-stimulating hormone receptor gene polymorphisms are not associated with ovarian reserve markers. Fertil. Steril. 97(3), 677-681 (2012).
54. Morón FJ, Ruiz A. Pharmacogenetics of controlled ovarian hyperstimulation: time to corroborate the clinical utility of FSH receptor genetic markers. Pharmacogenomics 11(11), 1613-1618 (2010).
55. Gleicher N, Weghofer A, Barad DH. Effects of race/ethnicity on triple CGG counts in the FMR1 gene in infertile women and egg donors. Reprod. Biomed. Online 20(4), 485-491 (2010).
56. Hagerman RJ. Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. J. Dev. Behav. Pediatr. 27(1), 63-74 (2006).
57. Hagerman RJ, Leehey M, Heinrichs W et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57(1), 127-130 (2001).
58. Sullivan AK, Marcus M, Epstein MP et al. Association of FMR1 repeat size with ovarian dysfunction. Hum. Reprod. 20(2), 402-412 (2005).
59. Wittenberger MD, Hagerman RJ, Sherman SL et al. The FMR1 premutation and reproduction. Fertil. Steril. 87(3), 456-465 (2007).
60. Allen EG, Sullivan AK, Marcus M et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum. Reprod. 22, 2142-2152 (2007).
61. Gleicher N, Weghofer A, Oktay K, Barad DH. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test? Acta Obstet. Gynecol. Scand. 88(9), 1024-1030 (2009).
62. Gleicher N, Weghofer A, Oktay K, Barad D. Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve. Reprod. Biomed. Online 19(3), 385-390 (2009).
63. Bibi G, Malcov M, Yuval Y et al. The effect of CGG repeat number on ovarian response among fragile X premutation carriers undergoing preimplantation genetic diagnosis. Fertil. Steril. 94(3), 869-874 (2010).
64. Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet 2(8560), 645-647 (1987).
65. Maheshwari A, Gibreel A, Bhattacharya S, Johnson NP. Dynamic tests of ovarian reserve: a systematic review of diagnostic accuracy. Reprod. Biomed. Online 18(5), 717-734 (2009).
66. Kwee J, Schats R, McDonnell J, Schoemaker J, Lambalk CB. The clomiphene citrate challenge test versus the exogenous follicle-stimulating hormone ovarian reserve test as a single test for identification of low responders and hyperresponders to in vitro fertilization. Fertil. Steril. 85(6), 1714-1722 (2006).
67. La Marca A, Argento C, Sighinolfi G et al. Possibilities and limits of ovarian reserve testing in ART. Curr. Pharm. Biotechnol. 13(3), 398-408 (2012).
68. Nelson SM, Lawlor DA. Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144,018 treatment cycles. PLoS Med. 8(1), e1000386 (2011).
69. Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertil. Steril. 95(7), 2364-2368 (2011).
70. Zhang D, Zhu Y, Gao H et al. Overweight and obesity negatively affect the outcomes of ovarian stimulation and in vitro fertilisation: a cohort study of 2628 Chinese women. Gynecol. Endocrinol. 26(5), 325-332 (2010).
71. Verhagen TE, Hendriks DJ, Bancsi LF, Mol BW, Broekmans FJ. The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis. Hum. Reprod. Update 14(2), 95-100 (2008).
72. Broer SL, van Disseldorp J, Broeze KA et al.; on behalf of the IMPORT Study Sroup. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum. Reprod. Update 19(1), 26-36 (2013).